NCT05499065View on ClinicalTrials.gov

Real-time Margin Assessment in Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

October 23, 2024

Study Completion Date

January 10, 2025

Conditions
Head and Neck CancerHead and Neck Squamous Cell Carcinoma
Interventions
PROCEDURE

Fluorescence guided detection of tumor positive margins

To test if the fluorescence can guide the location for fresh frozen section sampling intra-operatively

DRUG

Cetuximab-IRDye800

Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER